Khiev Dawin, Mohamed Zeinab A, Vichare Riddhi, Paulson Ryan, Bhatia Sofia, Mohapatra Subhra, Lobo Glenn P, Valapala Mallika, Kerur Nagaraj, Passaglia Christopher L, Mohapatra Shyam S, Biswal Manas R
MSPN Graduate Programs, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA.
Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA.
Nanomaterials (Basel). 2021 Jan 12;11(1):173. doi: 10.3390/nano11010173.
Ocular diseases can deteriorate vision to the point of blindness and thus can have a major impact on the daily life of an individual. Conventional therapies are unable to provide absolute therapy for all ocular diseases due to the several limitations during drug delivery across the blood-retinal barrier, making it a major clinical challenge. With recent developments, the vast number of publications undergird the need for nanotechnology-based drug delivery systems in treating ocular diseases. The tool of nanotechnology provides several essential advantages, including sustained drug release and specific tissue targeting. Additionally, comprehensive in vitro and in vivo studies have suggested a better uptake of nanoparticles across ocular barriers. Nanoparticles can overcome the blood-retinal barrier and consequently increase ocular penetration and improve the bioavailability of the drug. In this review, we aim to summarize the development of organic and inorganic nanoparticles for ophthalmic applications. We highlight the potential nanoformulations in clinical trials as well as the products that have become a commercial reality.
眼部疾病会使视力恶化至失明程度，从而对个人日常生活产生重大影响。由于药物透过血视网膜屏障递送过程中存在诸多限制，传统疗法无法为所有眼部疾病提供彻底治疗，这成为一项重大临床挑战。随着近期的发展，大量出版物证实了基于纳米技术的药物递送系统在治疗眼部疾病方面的必要性。纳米技术工具具有若干重要优势，包括药物持续释放和特定组织靶向性。此外，全面的体外和体内研究表明纳米颗粒能更好地跨越眼部屏障被摄取。纳米颗粒可克服血视网膜屏障，从而增加眼部药物渗透并提高药物生物利用度。在本综述中，我们旨在总结用于眼科应用的有机和无机纳米颗粒的发展情况。我们着重介绍了临床试验中的潜在纳米制剂以及已成为商业现实的产品。
